Key facts
- Zafrens’s last known valuation is $53.0M (Feb 2025).
- It has raised $32.0M across 1 recorded rounds; the latest was Early Stage VC ($6.2M) in Dec 2021.
- Notable investors include Global Brain, Liquid 2 Ventures, Acequia Capital, Hawktail, Possible Ventures — 14 tracked in total.
- Zafrens has filed 1 Form D with the SEC, most recently Jan 2022 ($6.2M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Zafrens
Funding rounds
1 roundsAbout Zafrens
Developer of life sciences products designed to generate insights at the interface of biology, chemistry, and engineering. The company offers a resolution approach to studying cell-drug and cell-cell interactions by direct mapping of molecular states of single cells at a time, and the large volumes of curated experimental insights are being used to train artificial intelligence models for drug discovery, enabling the medical industry with internal expertise in T cell immunotherapies and ribonucleic acid regulation based on proprietary data and experimental capabilities.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 28
- Website
- zafrens.com/
- Ownership
- Privately Held (backing)
Zafrens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zafrens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zafrens in its N-PORT filings yet. We sweep new filings monthly.